this is not good...the beeners are still dominating..specting more in asia and indai....not fathoming well..
bump. with just a couple weeks before Q2 results are revealed, I think it is essential for any investor or potential investor in Infosonics to listen to the CEO in this interview.
People often listen to an earnings conference call to try to glean some meaning from the careful words of management, but in this interview Ram basically puts his cards on the table, in my opinion.
Thanks. It's not my type on fundamentals (balance sheet tangible book, etc.) but it's got a good cash position and for a bio, it is appealing on this news, for sure. I got some this A.M. at .65. Thank you, friend.
Your list of support centers is further telling of new marketplaces
If they can average a little less than .08 a share each quarter - we are looking at say .30 for a year. At a PE of 20.........I believe we will be in the 5-7 range in short order. The PE and earnings estimate here are probably both real conservative. How this has stayed under 3 for this long is just crazy but I sure appreciate it.
NORTH AMERICA & CARIBBEAN: 3
DOMINICAN REPUBLIC 1
PUERTO RICO 1
MEXICO & CENTRAL AMERICA: 15
COSTA RICA 1
EL SALVADOR 2
SOUTH AMERICA : 11
29 Support Centers to take care of their customers! Awesome. IFON, with its market cap under $45M, is hugely undervalued, imo.
Sentiment: Strong Buy
forward PE after this report at 15 per share will be around 20 times. Some think they will do a dollar or more in the 4 quarters after this report. We expect them to raise some money though after the q3 or q4 report and the new shares will likely not allow for a full 1.00 per share. But who knows they are are in the right spot with the right products at the right time and the growth is explosive.
Curious. What would the P/E ratio be at a pps of $15 and how do you justify that on a forward growth multiple?
I'm all for a run here but $15 is a little frothy.
If anyone is interested in taking a look...Alzheimer's clinical stage Bio.
Wednesday, July 22, 2015
Anavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer’s Disease at AAIC 2015GlobeNewswire( (Wed 7:00AM EDT)